Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Share Dealings

23rd Dec 2014 16:05

SHIRE PLC - Director/PDMR Share Dealings

SHIRE PLC - Director/PDMR Share Dealings

PR Newswire

London, December 23

Director/PDMR Share Dealings December23, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announcesthat Ordinary Shares ("Shares") and American Depositary Shares ("ADSs") of theCompany, as set out below, have been acquired today for the Non-ExecutiveDirectors, being the part of their total fees that are paid in shares for theperiod of service from October 1 to December 31, 2014. Type of Security(1) Number of Shares/ADSs Dominic Blakemore Shares 122 William Burns Shares 119 Dr. Steven Gillis ADSs 37 Dr. David Ginsburg ADSs 41 David Kappler Shares 123 Susan Kilsby (2) ADSs 150 Anne Minto Shares 119 David Stout ADSs 37 (1) One ADS is equal to three Shares. (2) On October 23, 2014, Susan Kilsby's fee as Chairman of Shire plc wasincreased to £450,000 per annum effective as of September 1, 2014. Twenty-fiveper cent of this amount will continue to be paid in stock. The number of ADSsacquired for Ms Kilsby, as referenced above, includes ADSs acquired in respectof the pro rata amount of her fee increase for the month of September, 2014. The Shares and ADSs were acquired on the London Stock Exchange and NASDAQrespectively at £46.4937 per Share and $217.4953 per ADS. This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)of the Disclosure and Transparency Rules. Tony GuthrieDeputy Company Secretary For further information please contact: Investor Relations Jeff Poulton [email protected] +1 781 482 0945 Sarah Elton-Farr [email protected] +44 1256 894157 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We focus on providing treatments in Rare Diseases, Neuroscience,Gastrointestinal, and Internal Medicine and we are developing treatments forsymptomatic conditions treated by specialist physicians in other targetedtherapeutic areas, such as Ophthalmics. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com

Related Shares:

Shire
FTSE 100 Latest
Value8,600.83
Change-2.09